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ABSTRACT 
Motivated by the necessity of new and efficient methods for dietary gluten control of celiac patients, 
we have developed a simple and highly sensitive SPR biosensor for the detection of gluten peptides in 
urine. The sensing methodology enables rapid and label-free quantification of the gluten immunogenic 
peptides (GIP) by using G12 mAb. The overall performance of the biosensor has been in-depth 
optimized and evaluated in terms of sensitivity, selectivity and reproducibility, reaching a limit of 
detection of 0.33 ng·mL-1. Besides, the robustness and stability of the methodology permit the 
continuous use of the biosensor for more than 100 cycles with excellent repeatability. Special efforts 
have been focused on preventing and minimizing possible interferences coming from urine matrix 
enabling a direct analysis in this fluid without requiring extraction or purification procedures. Our SPR 
biosensor has proven to detect and identify gluten consumption by evaluating urine samples from 
healthy and celiac individuals with different dietary gluten conditions. This novel biosensor 
methodology represents a novel approach to quantify the digested gluten peptides in human urine with 
outstanding sensitivity in a rapid and non-invasive manner. Our technique should be considered as a 
promising opportunity to develop Point-of-Care (POC) devices for an efficient, simple and accurate 
gluten free diet (GFD) monitoring as well as therapy follow-up of celiac disease patients. 
 
KEYWORDS: surface plasmon resonance; gluten immunogenic peptides; 33-mer gliadin peptide, 
gluten detection, celiac disease, POC device 
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1. INTRODUCTION 
Celiac disease (CD) is a chronic autoimmune disorder induced in genetically susceptible individuals 
by the ingestion of gluten proteins contained in wheat, barley, rye and certain varieties of oats. The 
disease is triggered by the presence of partially digested gluten peptides in the gastrointestinal tract, 
part of them are highly reactive to celiac T cells causing inflammation of the small intestine (Comino 
et al. 2011; Denham and Hill 2013). The only effective treatment for CD is a lifelong gluten-free diet 
(GFD). The strict adherence to a GFD is crucial to resolve symptoms and nutritional deficiencies, but 
also to avoid clinical complications associated with long-term gluten intake in celiac patients, such as 
osteoporosis, anemia or malignancy (Freeman 2012). It is generally recommended that individuals 
suffering CD have a careful therapy follow-up and dietary control. Extensive clinical guidelines have 
been reported about the importance of long-term monitoring of CD patients (Rubio-Tapia et al. 2013). 
However, the current markers for an efficient dietary control still remain unclear and the available 
methods involve risky and costly procedures (Silvester and Rashid 2007). Serological analysis of IgA 
antibodies involved in CD immunopathogenesis (e.g. tissue transglutaminase antibodies) have shown 
poor specificity and sensitivity for detecting either adherence to a GFD or intestinal damage recovery 
(Walker and Murray 2011). The use of serial endoscopies or biopsies is not useful neither since it is 
not considered ethical practice. Other suggested dietary controls, such as the fecal calprotectin test or 
intestinal permeability tests, can measure the consequences of gluten intake but they do not avoid the 
harmful aftermaths, they require expensive laboratory analysis and they are not concluding about the 
adherence to a GFD (Duerksen et al. 2005; Ertekin et al. 2010). Hence, a more direct and non-invasive 
control of gluten ingestion could trigger a significant progress towards the fabrication of the reliable 
Point-of-Care (POC) devices that would facilitate a continued follow-up of GFD compliance and 
therapy assessment. 
Previous studies have highlighted the α-gliadin 33-mer peptide as a valuable marker for gluten 
detection (Bethune et al. 2009). The gliadin 33-mer peptide is resistant to breakdown by 
gastrointestinal enzymes and persists in the gut, being the major cause of the immunotoxicity of wheat 
gluten. Antibodies against the dominant immunogenic peptide α-gliadin 33-mer, A1 and G12 mAbs,  
have demonstrated to be practical tools to detect specifically the most active gluten immunogenic 
peptides (GIP) not only in food and beverages (Comino et al. 2013; Morón et al. 2008b; Real et al. 
2014) but also in human stool after gluten intake (Comino et al. 2012). Comino et al. proved the 
feasibility of quantifying gluten peptides in feces employing the G12 mAb and evidenced its 
usefulness as indicator of gluten ingestion for dietary monitoring. However, feces analysis requires 
protein extraction and sample pretreatment to be done in laboratory infrastructures that restrict the 
final implementation in POC devices. 
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The combination of more easy-to-handle samples such as urine and user-friendly biosensors could be 
very convenient for the development of portable and simple devices for the GFD compliance of celiac 
patients. Biosensors offer significant advantages over conventional techniques (e.g. mass 
spectrometry) enabling biochemical analysis with high sensitivity and excellent reproducibility in few 
minutes. Among them, optical biosensors and, especially, Surface Plasmon Resonance (SPR) 
biosensors play an outstanding role due to their ability to detect and quantify target compounds in real 
time without the use of labels or amplification steps. SPR biosensors exploit the high sensitivity of an 
evanescent field generated at the interface of a nanometric metal layer (typically Au layer of ~ 50 nm 
thickness) and a dielectric when light strikes the interface under appropriate angle conditions. The 
properties of the evanescent field are highly dependent on the refractive index (RI) of the external 
media in such a way that small changes like those induced by biomolecular interactions (Homola 
2008) can be measured. Biological recognition events occurring on the sensor surface can be 
monitored by tracking alterations in the characteristics of the reflected light, like the intensity or the 
resonance wavelength position. SPR biosensors have demonstrated their versatility as analytical 
platforms to monitor biomolecular interactions and to detect a wide range of analytes in a vast number 
of fields, including food safety, environmental monitoring or medical diagnostics and therapy control 
(Homola 2008). 
By using specific antibodies against the peptide α-gliadin 33-mer we have developed a novel 
methodology based on an indirect competitive immunoassay for the detection of most relevant GIP in 
urine employing a SPR biosensor. The optimization of the immunoassay has been directed towards the 
enhancement of the analytical features and especially to deal with possible interferences coming from 
the urine matrix. The rapid and quantitative detection of GIP in urine achieved with the SPR sensor 
exemplifies an attractive approach for the achievement of next-generation non-invasive and label-free 
analytical tools for the development of a POC device for dietary control of celiac patients.  
2. MATERIALS AND METHODS 
2.1. Reagents 
Acetone, ethanol and hydrochloric acid were provided by Panreac (Barcelona, Spain). Alkanethiols for 
SAM formation (16-mercaptohexadecanoic acid (MHDA) and 11-mercaptoundecanol (MUOH), 
reagents for carboxylic groups activation (1-ethyl-3(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) and sulfo-N-hydroxysuccinimide (s-NHS), and Tween 20 were purchased from 
Sigma Aldrich (Steinhem, Germany). Copolymer poly-L-lysine grafted polyethylene glycol (PLL(20)-
g[3.5]-PEG(2)) was from Susos (Dübendorf, Switzerland). Monoclonal antibody G12, prolamin 
working group (PWG) gliadin and 33-mer gliadin peptide were from Biomedal S.L. (Seville, Spain).  
2.2. Study patients and urine sampling 
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The local Ethics Committee of the Hospital de Valme (Seville, Spain) approved the study protocol. 
Written consent was obtained from adult patients and, in the case of children, from parents or legal 
guardians. Exclusion criteria for all study patients included the presence of known medical disease, 
use of prescription medications and antibiotics in the 2 months prior to the inclusion in the study. 
Moreover, healthy patients had no digestive disease symptoms or family history of CD.  
All participants were provided of sterile containers. Urine specimens (50-100 mL) from volunteers 
were collected and stored at -20ºC until analysis. Urines from healthy subjects and celiac patients were 
collected under different gluten dietary conditions and times, as follows: (1) for the optimization and 
assessment, urines from celiac patients on strict GFD (> 2 years) were used, (2) to test the usefulness 
of the method, urines from healthy individuals on normal gluten containing diet were collected. All the 
samples were previously analyzed by using proprietary method of Biomedal (Seville, Spain) with a 
lateral flow test (Moreno et al. 2015; submitted). 
2.3. SPR biosensor description 
We employed a homemade SPR sensor based on the Kretschmann configuration, working at a fixed 
angle of incidence and monitoring the binding events in real time by tracking the SPR-wavelength 
displacements (ΔλSPR). Gold sensor chips (glass surface coated with 1 nm of Ti and 45 nm of Au) were 
clamped between a trapezoidal glass prism contacting the sample through RI matching oil (n ≈ 1.512) 
and a custom-made Delrin flow cell (volume = 4 µL), which is connected to a delivery microfluidic 
system consisting on a syringe pump with adjustable pumping speed that ensured a constant liquid 
flow and a manually operated injection valve. The sensor surface is excited by a collimated halogen 
light source set in TM polarization. The light reaches the substrate at a fixed angle of incidence (θ = 
70°) through the prism coupling and the reflected light is collected and fiber-coupled to a CCD 
spectrometer (Jazz Module, Ocean Optics, USA). Tracking of the real-time resonance peak position is 
achieved via polynomial fit using custom-made readout software. The obtained sensorgrams show the 
displacements of the λSPR to lower energy (higher RI, binding event) or higher energy (lower RI, 
unbinding event). Experiments were carried out keeping a constant flow rate of 25 µL·min-1 for target 
recognition, and of 50 µL·min-1 for regeneration. Total sample analysis was 20 min (40 min when 
including preincubation with the antibody and the regeneration step). Gold surface 
biofunctionalization is described in the Supporting Information. 
2.4. Competitive immunoassay performance 
To study the performance of the competitive immunoassay, PBST (PBS + 0.5% Tween 20) was set as 
running buffer. The sample containing gluten peptides was preincubated for 15 min with a fixed 
concentration of antibody (2 µg·mL-1) at room temperature (RT) in gentle agitation. The mixture was 
flowed over the biofunctionalized surface and binding event was monitored, obtaining signals 
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inversely proportional to the concentration of the analyte in the sample. Regeneration of the PWG 
gliadin layer was carried out by injecting 5 mM HCl solution. 
Calibration curves were obtained measuring different concentrations of gliadin 33-mer peptide by 
triplicate. Calibration curve fitting is described in the Supporting Information. 
3. RESULTS AND DISCUSSION 
3.1. Design of the biosensor strategy 
By using the G12 mAb, we have designed a SPR-based indirect competitive immunoassay for the 
label-free detection of GIP, including the -gliadin 33mer peptide that is used as standard.  In this 
format, the antigen or an analogous molecule is immobilized on the sensor surface and a fixed 
concentration of antibody is incubated with the sample containing the free target analyte. Then, the 
mixture is flowed onto the functionalized surface where free unbound antibodies (i.e. antibodies that 
have not interacted with the analyte in the sample) are captured by the immobilized antigen layer 
generating a signal inversely proportional to the analyte concentration in the sample. Competitive 
immunoassay was chosen over direct immunoassay (where the antibody is immobilized onto the 
sensor surface and the analyte is directly detected from the sample) because of the small size of 
excreted gluten peptides (MW ~ 3.9 kDa). SPR detection is based on alterations of the RI of the 
dielectric caused by mass changes; thereby low molecular weight analytes (< 5 kDa) induce minute RI 
changes that can hinder the direct detection at low concentrations. Furthermore, competitive assays 
offer certain benefits in terms of robustness when compared to direct immunoassays. Generally, the 
immobilization of antibodies on solid supports diminishes their biological activity either by alteration 
of the antigen binding sites or due to the use of harsh conditions to regenerate the biosurface. In 
contrast, competitive immunoassay employs native or intact antibodies for the analyte recognition and 
the immobilization of the antigen usually provides a higher surface stability and allows the 
reutilization of the device for a higher number of measurements. However, it is also especially 
important in indirect competitive immunoassays the selection of a proper coating antigen, which, in 
combination with the specific antibody, is going to define the sensitivity and specificity of the final 
assay. In our work, both the -gliadin 33-mer peptide and the whole gliadin protein are good 
candidates for the development of the competitive assay. The 33-mer peptide comes precisely from the 
gluten hydrolysis and both have been previously used in the development of competitive ELISA using 
the same specific antibody (Morón et al. 2008a; Morón et al. 2008b).  
Whereas for conventional ELISA the simple adsorption of the antigens on the solid support is optimal 
and commonly the preferred option, in the case of biosensors this step becomes more critical and the 
achievement of optimal performance strongly depends on the surface functionalization. The strategy 
for gold chip modification and the grafting density of the antigen are crucial factors to enhance the 
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efficiency of the immunoassay and also to modulate and eventually minimize undesired nonspecific 
effects when real samples are evaluated. SPR gold chips are commonly functionalized taking 
advantage of the thiol-gold chemistry, which provides a strong attachment of thiol-modified molecules 
to gold surfaces by chemisorption. We employed long-chain alkanethiol compounds 
(mercaptohexadecanoic acid, MHDA, and mercaptoundecanol, MUOH) in order to create a tight and 
uniform self-assembled monolayer (SAM) onto the gold substrate. Carboxylic acid groups of the SAM 
are used for covalent coupling of biomolecules by means of a carbodiimide-mediated linkage to 
exposed amine groups, usually from terminal lysine (K) residues, establishing an amide bond. This 
strategy assures the high stability of the biofunctionalized surface and enables the control of the 
grafting density of antigens by varying the ratio of carboxylic/hydroxyl groups (MHDA:MUOH). As 
the gliadin 33-mer peptide does not carry any K residue within its amino acid sequence 
(LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF), we selected the protein (gliadin) as coating 
antigen (competitor in the indirect immunoassay). In particular we used the prolamin working group 
PWG gliadin (MW ~ 33-45 kDa), which is considered an international reference reagent in gluten 
analysis due to the high content of gliadins, good solubility, homogeneity and stability (Van Eckert et 
al. 2006). A schematic representation of the SPR biosensing strategy is depicted in Figure 1.  
 
3.2. Optimization of the 33-mer gliadin peptide competitive immunoassay 
An in-depth optimization of the overall biosensing strategy was carried out to maximize the analytical 
features of the assay, in terms of sensitivity, selectivity and reproducibility. We evaluated several 
parameters, such as the surface biofunctionalization (SAM composition and antigen concentration), 
the fixed antibody concentration and the preincubation time. For the optimization study we employed 
a synthetic gliadin 33-mer peptide as target analyte. A detailed discussion of the optimization process 
and the results obtained are shown in the Supporting Information (SI). First, we tested different 
carboxylic/hydroxyl SAM ratios for PWG gliadin immobilization by comparing the efficiency to 
detect the G12 mAb being the ratio of CO2H:OH of 1:1 the optimum one (see Figure S1.A in the SI). 
Immobilized gliadin and antibody concentrations were also selected according to the results obtained 
from titration experiments (noncompetitive recognition curves) as summarized in Figures S1.B and 
S1.C in the SI). We selected a concentration of PWG gliadin of 50 µg·mL-1 and an antibody 
concentration of 2 µg·mL-1. A preincubation step of 15 minutes led to complete signal inhibition (data 
not shown). This period was enough to ensure the formation of the immunocomplex and was fixed for 
further experiments. Regeneration of the PWG gliadin layer was also achieved under acid conditions 
(5 mM HCl) (Figure S1.E in the SI) being possible more than 100 cycles with good repeatability. 
Additionally, we assessed the specificity of the assay by evaluating either a non-target protein which 
could also be found in the urine, the human Chorionic Gonadotropin, hCG, and a nonspecific antibody 
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(control antibody, anti-C-reactive protein) (Figure S1.D in the SI). On one hand, incubation of G12 
mAb with hCG at high concentration (2 µg·mL-1) led to no inhibition, (i.e. maximum signal was 
obtained as in the case of zero concentration of analyte); on the other hand, the use of a control 
antibody resulted in negligible adsorption onto the surface indicating that signal corresponds 
exclusively to specific interaction of G12 mAb with the gliadin surface. Although the recognition 
pattern and cross-reactivity studies of the antibody against closely related gluten peptides has been 
previously performed (Morón et al. 2008a), these results corroborate not only the inherent specificity 
of the antibody but specially the selectivity of the antigen-coated layer to exclusively interact with the 
G12 mAb. 
With all above selected conditions a calibration curve for the gliadin 33-mer peptide was obtained 
(Figure S1.F in the SI and Figure 2). An IC50 value of 5.64 ng·mL-1 was achieved. The limit of 
detection (LoD) and quantification (LoQ) were 0.33 and 1.12 ng·mL-1 respectively, and the linear 
working range was found between 1.12 – 19.20 ng·mL-1. The SPR-based immunoassay showed 
comparable features to the ones obtained using the same reagents in different ELISA configurations 
(LoD < 1 ng·mL-1) (Morón et al. 2008b). For evaluation of the reproducibility both intra- and inter-
assay Coefficients of Variability (CV) of the main analytical parameters were calculated (Table 1). 
The mean values for the intra- and inter-assay CV were well-below the maximum variability 
recommended for clinical analysis (~ 15%) (Buick et al. 1990), confirming the excellent 
reproducibility and stability of the proposed immunoassay. 
 
3.3. Analysis of 33-mer gliadin peptide in urine matrix 
The urine is one of most attractive biological fluids for dietary control analysis due to the simple and 
non-invasive sample collection. Moreover, it can be obtained in large amounts. However, there are 
several limitations for the urinary analysis mainly related to low concentration of proteins, the high 
levels of salts or other interfering compounds and, more importantly, the high degree of variability. 
Parameters like pH, osmolality, gravity or the concentration of certain components vary over a wide 
range between different specimens, the diet or the collection time (Sviridov and Hortin 2009). This 
large variability of urine samples represents an important barrier for the reliable detection and 
quantification of clinical biomarkers. To our knowledge, so far scarce studies have been reported for 
the label-free detection of small peptides in urine. Current analytical methods are usually based in 
mass-spectrometry techniques which are expensive and time-consuming, and require laborious 
pretreatment and extraction processes (Decramer et al. 2008). Hence, SPR-based biosensing of 
peptides in urine in general would have a great potential for fast and efficient clinical assays as well as 
for biomarker discovery. Nevertheless, the influence of matrix interferences and variability needs to be 
deeply optimized to provide accurate and reliable results. 
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The feasibility of direct detection of gliadin 33-mer peptide in urine employing the biosensor was 
evaluated by studying the influence of the matrix components present in the fluid in the competitive 
assay performance. Although protein concentration is relatively low compared to other biological 
fluids like serum or plasma, normal healthy urine contents a total protein concentration between 50 – 
100 µg·mL-1, and albumin can represent up to 20 µg·mL-1 (Brunzel 2013). In SPR biosensors, where 
the signal comes indirectly from mass changes onto the sensor surface, the adsorption of proteins may 
lead to undesired nonspecific signals that must be minimized. In previous work, we evidenced the 
extraordinary resistance to protein fouling provided the copolymer poly-L-lysine grafted polyethylene 
glycol (PLL-g-PEG) as blocking additive (Soler et al. 2014; Soler et al. 2015). Therefore a blocking 
step with PLL-g-PEG (0.5 mg·mL-1) after PWG gliadin immobilization was carried out to prevent 
nonspecific adsorptions of urine components. Moreover, running buffer was changed to PBST 0.5% 
(PBS with 0.5% of Tween 20, whose addition in the media has demonstrated to also help reduce the 
nonspecific fouling onto the surface (Soler et al. 2014)). The background signal observed under these 
conditions was low enough and highly reproducible (standard deviation below 0.01 nm) to permit 
reliable detection of the peptides in urine (data not shown), thereby assuming a constant background 
for all measurements. On the other hand, the presence of proteins, the high salt concentration or the pH 
value may also affect the interaction between the antibody and the biofunctionalized surface, leading 
to important variations of the immunoassay behavior (i.e. alteration in the maximum signal, the slope 
and the detectability). The G12 mAb was diluted in different gluten-free urine samples collected from 
several individuals following strict GFD and evaluated with the SPR biosensor (data not shown). A 
significant variability of the signal (maximum signal at zero concentration of analyte) was obtained 
(CV = 23.08%), which is attributed to the composition variability of the urine samples. In order to 
stabilize the behavior of the assay, urine samples were buffered by diluting them with PBST 0.5% 
(1:1). The variability (CV) was reduced to 2.6%, improving the reproducibility and increasing the 
reliability of the measurements. 
A calibration curve in urine diluted 1:1 with PBST 0.5% was carried out using gliadin 33-mer as target 
analyte. Figure 2 shows and compares curves obtained for spiked GF urine and PBS buffer. Matrix 
constituents of urine did not produce significant interferences in the competitive immunoassay, 
leading to nearly identical analytical sensitivity than the one obtained in standard buffer conditions. 
The IC50 was determined at 5.06 ng·mL-1, reaching a LoD of 0.46 ng·mL-1 and a dynamic range 
between 1.20 – 21.55 ng·mL-1. The sensitivity values achieved are comparable to those obtained with 
conventional ELISA, which are several orders of magnitude below the maximum recommended gluten 
concentration in the digestive tract (i.e. < 20 μg·mL-1) (Catassi et al. 2007; Morón et al. 2008b). 
Moreover, our SPR-based assay permits rapid and label-free analysis of urine in a user-friendly 
performance without requiring any sample pretreatment which commonly results in 100-fold sample 
dilutions prior to the analysis.  
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3.4. Determination of gluten toxic peptides patient samples 
To evaluate whether our proposed SPR biosensing methodology was suitable to detect gluten toxic 
peptides in celiac patients, the analysis of real urine samples was attempted. So far, the experiments 
have been performed using the gliadin 33-mer peptide as standard analyte. As detailed before, the G12 
mAb was produced against the gliadin 33-mer peptide from wheat gluten. However cross-reactivity 
experiments demonstrated the ability of the antibody of recognizing other immunogenic peptides from 
wheat and other toxic cereals for celiac, such as those from barley or rye (Morón et al. 2008a), with 
different degree of recognition and affinity. Therefore, the presence in urine of immunogenic peptides 
with different sequences from different cereal sources (equivalent peptides (33EPs)) would be 
expected, that will eventually react with the antibody and hence would be quantified. Besides, the 
gliadin 33-mer peptide is involved in numerous metabolic processes that could alter its structure or 
amino acid sequence, such as the transglutaminase-mediated deamidation (Morón et al. 2008a; Shan et 
al. 2002). These factors can influence on the immunoassay behavior, affecting the sensitivity of the 
analysis. Therefore, in order to have a more realistic standard analyte, we performed the biosensor-
based immunoassay using as analyte the peptide mixture obtained from a urine sample from a healthy 
individual following a normal gluten-containing diet. The concentration of 33EPs in the sample was 
determined employing lateral-flow chromatographic strips and specific strip reader (Martin et al. 
2014). In addition, part of this urine sample was subjected to an extraction and purification procedure 
obtaining a 33EP extract in PBS buffer. The purification procedure was performed using Biomedal SL 
proprietary technology. Both samples (untreated urine and PBS extract) contained a mixture of 
peptides at a concentration of [33EPs]= 20 ng·mL-1. The samples were pre-concentrated and then 
serially diluted either in buffer or in GF urine, respectively, in order to cover the concentration range 
necessary to define the assay. Competitive assays were performed applying the optimized conditions 
described before. Figure 3 shows the calibration curves (green and blue lines) which were compared to 
the ones previously obtained using 33-mer gliadin peptide as pure standard (black and orange lines).  
As can be observed, the detectability of the immunoassay was slightly worse (i.e. curves are shifted to 
higher analyte concentration range), leading to higher limits of detection (Table 2). The IC50 
determined for 33EP detection in urine was 18.58 ng·mL-1 and the LoD was 1.72 ng·mL-1. These 
results can be attributed either to the presence of several peptide variants from different cereals, all of 
them with different affinity degree for the antibody and also to the probable presence of peptides 
containing structural modifications occurring during the metabolic processes. Both aspects eventually 
affect the resultant averaged sensitivity. However, it must be highlighted the high degree of similarity 
observed in the calibration curves performed in PBS and urine for the detection of 33EP in real 
samples (blue and green curves). These results obtained with a real mixture of gluten peptides confirm 
our previous results and demonstrates the viability of measuring directly in urine without the need of 
performing any kind of purification or extraction treatment. 
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Finally, we attempted a preliminary qualitative evaluation of real samples. We measured several urine 
samples containing different concentration of gluten in order to test the usefulness of the SPR 
biosensor to identify gluten ingestion. Urine samples were collected from celiac patients from the 
Hospital de Valme (Seville, Spain) and healthy volunteer individuals with different diet conditions: (i) 
volunteers under a gluten-free diet with no transgression, (ii) low consumption of gluten of celiac 
patients under GFD but with signs of transgressions (weak positive in the lateral flow test and/or 
incomplete gut mucosa healing) and (iii) moderate/normal consumption of gluten (normal gluten 
containing diet of 5-30g/day with quantifiable levels of 33EP in the lateral flow test and/or celiac 
patients with high damage in intestinal mucosa). Four samples of each group were measured. Each 
sample was only diluted 1:1 with PBST and incubated with G12 mAb for 15 min. The samples were 
then flowed over the functionalized sensor surface and measured in real time. Signals were 
interpolated in the calibration curve (Figure 3, green curve). Figure 4 compares the results obtained for 
each diet condition based on the determined statistical median of the interpolated concentration. 
Concentrations for every sample qualitatively correlate with the expected amount of gluten present in 
the urine. Besides, it can be observed a significant statistical difference between the individual 
populations. This result demonstrates that our SPR biosensor can be employed for monitoring the 
consumption of gluten by simple urine analysis and therefore opens up a way for the development of 
fast and easy-to-use POC devices for CD therapy follow-up. 
 
4. CONCLUSIONS 
We have developed a novel SPR biosensing methodology for simple and label-free detection of gluten 
toxic peptides in the urine of celiac patients. The strategy consists of a competitive immunoassay that 
employs a specific monoclonal antibody (mAb G12) with high affinity for gliadin 33-mer equivalent 
peptides (33EPs) coming from gluten proteins of wheat, barley and rye. The SPR biosensor has 
demonstrated to enable direct quantification of the small digestive peptides in urine without requiring 
previous extraction or purification procedures, performing the complete assay cycle in 20 min. Several 
parameters have been optimized in order to obtain reproducible, selective and sensitive analysis, 
achieving a LoD of 1.72 ng mL-1 in real urine samples. This value is well-below the maximum 
recommended gluten concentration in the digestive tract for CD patients (i.e. < 20 µg mL-1) (Morón et 
al. 2008b). The biosensing approach has also demonstrated the feasibility of clearly identifying gluten 
consumption by measuring several urine samples from both healthy (normal diet) and celiac subjects 
(gluten-free diet). The preliminary qualitative assay has shown significant statistical differences 
between individuals with different diet conditions (GFD, low gluten consumption, normal diet) as well 
as good correlation between the calculated concentration and the expected amount of gluten peptides 
in the urine. This SPR analytical methodology constitutes a first approach towards the achievement of 
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POC biosensors that permit rapid, accurate and non-invasive dietary control for the celiac disease 
follow-up.  
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FIGURE LEGENDS 
Figure 1. Scheme representing the three steps in the development of the SPR-based competitive 
immunoassay: formation of a mixed alkanethiol SAM; PWG gliadin immobilization via covalent 
coupling through the amine terminal groups; immunoassay where a competition between PWG gliadin 
and gluten immunogenic peptides (GIP) for the free antibody takes place. 
Figure 2. Calibration curves for the gliadin 33-mer peptide immunoassay in PBS buffer (black) and 
urine diluted 1:1 with PBST (orange). Each point represents the mean ± SD of three replicates. Table 
compares main analytical parameters determined for both curves. 
Figure 3. Calibration curves for competitive immunoassay of: (i) gliadin 33-mer peptide diluted in 
PBS (black); (ii) gliadin 33-mer peptide spiked in gluten-free urine (orange); (iii) Mixture of peptides 
(33EPs) extracted from purified positive urine diluted in PBS (blue) and (iv) Mixture of peptides 
(33EPs) from untreated positive urine diluted in gluten-free urine (green). 
Figure 4. Analysis of patient’s urine samples from individuals following a (i) gluten-free diet (n = 4), 
(ii) low gluten consumption diet (n = 4) and (iii) normal diet with high/moderate consumption of 
gluten (n = 4). Median, maximum and minimum values are shown. 
 
